VERTEX PHARMACEUTICALS INC / MA
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
Our policy governing transactions in our securities by our directors, officers, and employees permits our officers,
directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934,
as amended. The following table describes the written plans for the sale of our securities adopted by our directors and officers
(as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) duringthe third quarter of 2026, each of which is
intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”). Other than as described in the
table below, none of our directors or officers adopted, modified or terminated a Trading Plan in thethird quarter of 2026.
| Name and Title | Date of Adoption of Trading Plan | Scheduled Expiration Date of Trading Plan (1) | Maximum Shares Subject to Trading Plan |
|---|---|---|---|
| Kristen AmbroseSVP, Chief Accounting Officer | 8/06/2026 | 4/30/2027 | 5,422(2) |
| Sangeeta BhatiaDirector | 8/13/2026 | 7/30/2027 | 1,189 |
| Carmen BozicEVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer | 8/06/2026 | 7/30/2027 | 16,915(2) |
| Alan GarberDirector | 8/27/2026 | 7/30/2027 | 5,320 |
| Reshma KewalramaniChief Executive Officer and President, Director | 8/5/2026 | 12/1/2027 | 47,800 |
| Jeffrey LeidenExecutive Chairman | 8/5/2026 | 11/4/2027 | 18,411 |
| Joy LiuEVP, Chief Legal Officer | 8/21/2026 | 5/3/2027 | 20,764(2) |
| Bruce SachsDirector | 8/26/2026 | 7/20/2027 | 9,888 |
| Nancy ThornberryDirector | 8/15/2026 | 7/30/2027 | 2,571 |
| Charles F. Wagner, Jr.EVP, Chief Operating & Financial Officer | 8/10/2026 | 7/30/2027 | 15,286 |
| (1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan. | |||
| (2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable. | |||
Principal Accounting Officer
On October 30, 2026, the Company appointed Jonathan Oppenheim, our Vice President, Corporate Controller, as our
principal accounting officer, effective on February 15, 2027 (the “Effective Date”). On the Effective Date, Kristen Ambrose
will be appointed Senior Vice President, Global Business Operations and Transformation and will cease serving as our
principal accounting officer.
Jonathan Oppenheim, 56, has been our Vice President, Corporate Controller since August 2020. Mr. Oppenheim
previously served as Controller, US Business Unit at Takeda Pharmaceutical Company, a global biopharmaceutical company,
from January 2019 to August 2020. Prior to that, he served as Senior Director, Assistant Corporate Controller at Shire plc, a
biotechnology company, from November 2015 to January 2019, and Director, Technical Accounting at Thermo Fisher
Scientific Inc., a life sciences and clinical research company, from May 2010 to November 2015. Mr. Oppenheim received
his B.S. in Accounting from the University of Massachusetts Dartmouth and is a Certified Public Accountant.
There are no transactions involving the Company and Mr. Oppenheim that the Company would be required to report
pursuant to Item 404(a) of Regulation S-K. There is no arrangement or understanding between Mr. Oppenheim and any other
person pursuant to which Mr. Oppenheim was appointed as principal accounting officer.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.